Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism? Evidence From a Clopidogrel-to-Ticlopidine Crossover Study by Campo, Gianluca et al.
D
p
s
s
o
a
t
c
F
F
I
F
I
2
Journal of the American College of Cardiology Vol. 50, No. 12, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PAntiplatelet Therapy
Poor Responsiveness to Clopidogrel:
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Evidence From a Clopidogrel-to-Ticlopidine Crossover Study
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Roberto Ferrari, MD, PHD*†
Ferrara, Gussago, and Brescia, Italy
Objectives This study was designed to investigate whether poor responders to thienopyridines after clopidogrel remain so
even after ticlopidine administration (class effect) or whether a drug-specific effect exists between currently
available thienopyridines.
Background Whether clopidogrel poor responders also display inadequate platelet inhibition after ticlopidine administration
remains undefined.
Methods Platelet aggregation (PA) was measured in 143 patients, while they were taking aspirin, with light transmission ag-
gregometry using adenosine diphosphate as an agonist at baseline (T0) and at clopidogrel steady state (T1). After T1,
clopidogrel was stopped and substituted with ticlopidine. Then PA was assessed at ticlopidine steady state (T2). Resis-
tance was defined as an absolute difference between T0 and after-treatment (T1 or T2) PA 10%.
Results Clopidogrel and ticlopidine responsiveness was normally distributed; PA at T1 did not differ compared with T2.
Thirty (21%) and 28 (19%) patients were clopidogrel and ticlopidine nonresponders, respectively. Only 5 patients
(3.5%) were nonresponders to both clopidogrel and ticlopidine (class effect), whereas 25 patients (83%) who
were clopidogrel nonresponders at T1 were responsive to ticlopidine, reaching a higher level of platelet inhibition
at T2 (PA 69  15 vs. 44  18, p  0.01) (drug-specific response). On the other hand, 23 patients who were
responsive to clopidogrel showed resistance to ticlopidine at T2 (PA 46  15 vs. 70  15, p  0.01) (drug-
specific response).
Conclusions Poor responsiveness to either clopidogrel or ticlopidine at steady state was common, whereas nonresponders to
both drugs were relatively infrequent (3.5%, 95% confidence interval 1.5% to 7.9%), suggesting that poor re-
sponse to thienopyridines may frequently be a drug-specific mechanism. (J Am Coll Cardiol 2007;50:1132–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.092a
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Pual antiplatelet treatment based on administration of aspirin
lus ticlopidine (first-generation thienopyridine) has been
hown to be superior to aspirin alone in the prevention of
ubacute stent thrombosis (SAT) following percutaneous cor-
nary intervention (PCI). Because of its faster onset of action
nd improved safety profile (1), clopidogrel (second-generation
hienopyridine) has subsequently replaced ticlopidine.
Yet a large interindividual variability in the response to
lopidogrel is known to exist. Current available data show that
rom the *Cardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna,
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errara, Ferrara, Italy; and §Medical Statistics Unit, University of Brescia, Brescia,
taly.t
Manuscript received February 12, 2007; revised manuscript received March 28,
007, accepted April 9, 2007.bout 4% to 30% of patients do not display adequate antiplate-
et response (2–4), being poor responders at higher risk of
AT (5,6) or major adverse cardiac events (MACE) (7–9).
Whether poor responders to clopidogrel display similar
nadequate platelet inhibition after ticlopidine administra-
ion (class effect) remains undefined. We conducted a
rospective crossover study to investigate whether poor
esponders to thienopyridines after clopidogrel remain so
ven after ticlopidine administration (class effect) or
hether a drug-specific effect exists between currently
vailable thienopyridines.
ethods
atients. Individuals eligible for enrollment were pa-
ients undergoing PCI in our center from November
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September 18, 2007:1132–7 Clopidogrel Resistance: Drug-Specific?005 to May 2006. Exclusion criteria were glycoprotein
Ib/IIIa inhibitors, clopidogrel, or ticlopidine intake in
he preceding 30 days; or allergy to aspirin, clopidogrel,
r ticlopidine. Subjects were also excluded if they were
dmitted with non–ST-segment elevation acute coronary
yndrome, based on the established role of clopidogrel in
reventing recurrences (10). This study was approved by the
ocal ethics committee, and all patients gave written in-
ormed consent.
tudy design and specimen collection. Figure 1 shows a
tudy flow chart. Venous blood samples were collected at
he following time points: visit T0, baseline, before
hienopyridine administration; visit T1, clopidogrel
300-mg loading dose, followed by 75 mg/day) steady
tate (5 to 7 days after baseline); and visit T2, ticlopidine
teady state (7 to 10 days after T1). The timing of T1 was
elected on the basis of previous findings (2,3), suggesting
hat the maximum inhibitory response to standard clopi-
ogrel regimen occurs within 24 h and appears durable
ver 5 to 30 days. After T1, clopidogrel was substituted
y ticlopidine (500-mg loading dose, followed by 250 mg
wice daily). The timing of T2 allows clearance from
lopidogrel and ticlopidine-induced platelet inhibition at
teady state.
oncomitant drugs, PCI, and clinical follow-up. All
atients with ST-segment elevation myocardial infarction
STEMI) received aspirin (250 mg intravenously), heparin
50 to 70 U/kg), and glycoprotein IIb/IIIa inhibitors.
atients with stable angina (SA) received aspirin (100 mg
nce a day) at least 7 days and clopidogrel at least 6 h before
Figure 1 Study Design
CABG  coronary artery bypass graft; CAD  coronary artery disease; GP  glycop
patients; SA  stable angina; STEMI  ST-segment elevation myocardial infarctionrocedure. Aspirin (100 mg once
day) was given to all patients
ndefinitely, whereas thienopyri-
ines were given for 1 or 6
onths according to implanted
tent. Patients underwent outpa-
ient visits every 4 months. The
linical end points were death,
einfarction, target vessel revas-
ularization, or MACE.
latelet function testing. Plate-
et aggregation (PA) was per-
ormed as previously reported
11). Platelets were stimulated
ith 20 mol/l of adenosine
iphosphate. Platelet aggrega-
ion was measured at maximal
ggregation (Aggmax) and at 5 min (Agglate). Inhibition of
A (%IPA) was defined as the percent decrease in aggregation
alues (Aggmax) obtained at baseline and after treatment: (%PA
0  %PA T1 or T2)/%PA T0. Clopidogrel and ticlopidine
esistance was defined as: 1) absolute difference between
aseline and post-treatment Aggmax 10% (2,3); or 2)
IPA 20% (12).
tatistical analysis. Continuous data are presented as
ean  SD. Unpaired t tests were used for comparison of
ormally distributed continuous variables between 2 groups.
o account for multiple comparisons, we applied 2 linear
ixed models (Aggmax and Agglate) to estimate the varia-
ions of PA values, taking in account the intrasubject
Abbreviations
and Acronyms
CI  confidence interval
CYP  cytochrome P450
IPA  inhibition of platelet
aggregation
MACE  major adverse
cardiac event
PA  platelet aggregation
PCI  percutaneous
coronary intervention
SA  stable angina
STEMI  ST-segment
elevation myocardial
infarction
; NSTEACS  non–ST-segment elevation acute coronary syndrome; pts 
baseline; T1  clopidogrel steady state; T2  ticlopidine steady state.rotein
; T0 
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Clopidogrel Resistance: Drug-Specific? September 18, 2007:1132–7orrelation among the 3 measures. We have adopted as
andom effect the subject and a compound symmetry as
orrelation structure. Pearson’s correlation coefficients were
sed to detect any association between variables. A p value
0.2 was used as a threshold to define a normal distribution
ith the Kolmogorov-Smirnov test. Categorical variables
ere summarized in terms of number and percentages and
ere compared using the 2-sided Fisher exact test.
robability was significant at a level of 0.05. Analysis was
erformed using STATISTICA 7 (Statsoft Inc., Tulsa,
klahoma) and R-language (R Foundation).
esults
igure 1 illustrates the disposition of patients in the study.
heir clinical characteristics, laboratory data, and medica-
ions are shown in Table 1.
aseline PA. Baseline PA (Aggmax: 71 18; Agglate: 63
7) followed a normal distribution and was higher in
TEMI compared with SA (Aggmax: 77  17 vs. 65  18,
 0.01; Agglate: 69  15 vs. 57  16, p  0.01). The
resence of diabetes mellitus (r 0.3, p 0.01) and current
moking habit (r  0.2, p  0.01) were weakly related
o PA.
ffect of clopidogrel or ticlopidine. Compared with base-
ine, PA was significantly reduced after clopidogrel admin-
stration (Aggmax: 50  17 vs. 71  18, p  0.01; Agglate:
3  18 vs. 63  17, p  0.01). Response to clopidogrel
ollowed a normal distribution. After ticlopidine, PA re-
ained normally distributed and was significantly lower
han baseline (Aggmax: 49  17 vs. 71  18, p  0.01;
gglate: 43 19 vs. 63 17, p 0.01), whereas PA did not
Baseline Characteristics of the Patients
Table 1 Baseline Characteristics of the Pat
Characteristics
Whole Group
(n  143)
Age (yrs) 67  10
Men, n (%) 99 (69)
Body mass index (kg/m2) 28  7
Diabetes n (%) 32 (27)
Hypertension, n (%) 104 (73)
Smoker, n (%) 31 (22)
Prior CABG, n (%) 7 (5)
Prior PCI, n (%) 25 (17)
Prior MI, n (%) 26 (18)
Laboratory data
Platelet count (/ml) 260  90
White blood count (/ml) 10  5
Creatinine (mg/dl) 1.3  0.5
Fibrinogen (mg/dl) 410  140
Pharmacologic treatment†
Statins, n (%) 132 (92)
ACE inhibitors, n (%) 125 (87)
Beta-blockers, n (%) 97 (68)
*p value for the comparison between SA and STEMI groups; †all patie
ACE  angiotensin-converting enzyme; CABG  coronary artery
intervention; SA  stable angina; STEMI  ST-segment elevation myoiffer from values observed after clopidogrel (Aggmax: 49 7 vs. 50  17, p  0.5; Agglate: 43  19 vs. 43  18, p 
.5). Figure 2 illustrates the %IPA from baseline with
lopidogrel and ticlopidine.
lopidogrel or ticlopidine nonresponders. According to
efinition 1 (Fig. 3), 30 (21%, 95% confidence interval [CI]
4.6% to 28.7%) patients were classified as clopidogrel
onresponders (Table 2). They showed higher baseline PA
ompared with responders (Table 2). On the basis of
efinition 1 (Fig. 3), 28 (19%, 95% CI 14.7% to 26.8%)
ubjects were ticlopidine nonresponders (Table 2); their
aseline PA was again higher compared with ticlopidine
SA Group
(n  76)
STEMI Group
(n  67) p Value*
66  11 68  9 0.3
55 (72) 44 (66) 0.2
28  6 28  9 0.5
21 (27) 11 (16) 0.1
63 (84) 41 (61) 0.01
13 (17) 18 (26) 0.3
7 (9) 0 (0) 0.01
18 (23) 7 (10) 0.04
19 (25) 7 (10) 0.03
57  87 261  95 0.7
8  4 13  5 0.01
1.3  0.5 1.2  0.4 0.8
95  130 420  150 0.3
68 (90) 64 (95) 0.8
65 (85) 60 (90) 0.9
53 (70) 44 (65) 0.7
eived aspirin and thienopyridines.
graft; MI  myocardial infarction; PCI  percutaneous coronary
infarction.
Figure 2 Platelet Inhibition After Thienopyridine Treatment
Distribution of the percent inhibition of platelet aggregation from baseline to
after-treatment (clopidogrel steady state  solid bars; ticlopidine steady state
 open bars).ients
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September 18, 2007:1132–7 Clopidogrel Resistance: Drug-Specific?esponders (Table 2). Of note, diabetes mellitus was more
requent in nonresponders, whereas current smoking was
ncommon (Table 2). Twenty-five (83%, 95% CI 66% to
3%) patients who were clopidogrel nonresponders at T1
ere responsive to ticlopidine, reaching a higher level of
latelet inhibition at T2 (Table 3). On the other hand, 23
atients who were responsive to clopidogrel showed resis-
ance to ticlopidine at T2 (Table 3).
According to definition 2 (Fig. 3), 49 (34%, 95% CI 27 to
2.3) and 47 (33%, 95% CI 25.7 to 41) subjects were
lopidogrel and ticlopidine nonresponders, respectively.
Figure 3 Percentage of Nonresponders
Bars to the left of the dashed line  definition 1, absolute difference between
baseline and post-treatment Aggmax 10%. Bars to the right of the dashed
line  definition 2, %IPA 20%. IPA  inhibition of platelet aggregation.
haracteristics of the Patients Stratified According to Thienopyridi
Table 2 Characteristics of the Patients Stratified According to
Characteristics
Responders to Both
Thienopyridines
(n  90)
Age (yrs) 66  11
Men, n (%) 60 (67)
Diabetes, n (%) 12 (13)
Hypertension, n (%) 64 (71)
Current smoker, n (%) 27 (30)
Prior CABG, n (%) 4 (4)
Prior PCI, n (%) 15 (17)
Prior MI, n (%) 16 (18)
ST-segment elevation MI, n (%) 47 (52)
Maximal aggregation (Aggmax, %)
Baseline T0 68 16
Clopidogrel steady state T1 50 17†
Ticlopidine steady state T2 49 17†
Late aggregation (Agglate, %)
Baseline T0 63 17
Clopidogrel steady state T1 42 18†
Ticlopidine steady state T2 43 19†
onresponders according to definition 1. *p  0.05 versus responders. †p  0.01 versus T0. ‡
hienopyridines.
Abbreviations as in Table 1.aseline PA trended higher (74 13 vs. 69 16, p 0.09;
nd 73 16 vs. 70 15, p 0.1, respectively) and diabetes
ellitus tended to be more frequent (28% vs. 19%, p  0.1;
nd 28% vs. 20%, p  0.1, respectively) in the nonre-
ponders. Thirty-three of 49 clopidogrel nonresponders
ecame responsive to ticlopidine, whereas 31 subjects who
ere clopidogrel responders showed ticlopidine resistance
t T2.
ubjects being nonresponders to both clopidogrel and
iclopidine. According to definition 1, we identified only 5
atients (3.5%, 95% CI 1.5% to 7.9%) who were resistant to
oth clopidogrel and ticlopidine (Tables 2 and 3). Accord-
ng to definition 2, 16 patients (11.4%, 95% CI 7% to
7.4%) were nonresponders to both thienopyridines.
linical outcome. Table 4 shows MACE outcomes (me-
ian follow-up 210 45 days). Patients with adverse events
ad higher PA compared with those without (Aggmax: 83
6 vs. 67  17, p  0.01; Agglate: 75  13 vs. 62  15,
 0.01).
iscussion
he main findings of this prospective investigation can be
ummarized as follows:
. Responsiveness to either ticlopidine (first-generation
thienopyridine) or clopidogrel (second-generation
thienopyridine) followed a normal distribution, with a
percentage of nonresponders of roughly 20%.
. Patients resistant to clopidogrel are mainly responsive to
ticlopidine and vice versa. Only 5 of 143 patients (3.5%,
95% CI 1.5% to 7.9%) were poor responders to both
sponsiveness
opyridine Responsiveness
opidogrel
responders
n  30)
Ticlopidine
Nonresponders
(n  28)
Nonresponders to Both
Thienopyridines
(n  5)
9  8 68  7 71  3
24 (80) 19 (68) 4 (80)
12 (40)* 10 (35)* 2 (40)
22 (73) 22 (78) 4 (80)
2 (7)* 2 (7)* 0 (0)
2 (7) 1 (4) 0 (0)
7 (23) 4 (15) 1 (20)
8 (26) 3 (11) 1 (20)
17 (56) 14 (50) 2 (40)
6 13‡ 77 14‡ 80 6§
0 15 51 18† 76 5
8 20† 71 13 75 5
9 14‡ 69 15‡ 73 6§
4 15 44 18† 69 5
1 21† 63 13 70 5
1 versus T0 of responders to both thienopyridines. §p  0.05 versus T0 of responders to bothne Re
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resistance.
ecent data have demonstrated a marked variability in
esponse to standard dosing of clopidogrel, either after acute
oading (3,4) or maintenance dosing (13,14). A higher
oading dose of clopidogrel demonstrated an improved
lopidogrel response in the early hours, but this was not
ssociated with a reduction in the degree of interindividual
ariability (3,4). Poor responsiveness also occurs during
ustained clopidogrel treatment (13–15). Angiolillo et al.
15) have recently reported that doubling the maintenance
ose of clopidogrel enhances platelet inhibition. However,
esponse to antiplatelet therapy remained variable, and 60%
f patients remained poor responders. This has relevant
mplications, as recent studies (5–9) indicate that low
ntiplatelet effect of clopidogrel may be associated with a
igher risk of reinfarction or SAT. The American College
f Cardiology/American Heart Association/Society for
ardiovascular Angiography and Interventions guidelines
16) recommend the use of a 150-mg daily clopidogrel
aintenance dose in class IIa subjects in whom SAT may be
atastrophic and in whom an IPA 50% is demonstrated.
owever, the efficacy of this strategy has never been tested.
leil et al. (17) reported 3 cases in which clopidogrel was
neffective despite double dosing, whereas adequate re-
ponse to ticlopidine was obtained. Our present data are in
greement with this observation and confirm that, in pa-
ients in whom clopidogrel administration is associated with
nadequate response, switching to ticlopidine may lead to an
dequate platelet inhibition in 83% of cases (95% CI 66% to
3%). We believe that this finding may carry both patho-
hysiological and clinical implications.
Clopidogrel is absorbed rapidly from the gastrointestinal
ract; 85% of the prodrug is hydrolyzed by esterase in the
ggmax and Agglate Values in Patients Stratified According to Resp
Table 3 Aggmax and Agglate Values in Patients Stratified Accor
Responders to Both
Thienopyridines
(n  90)
Clopidog
Ticlop
Aggmax Agglate Aggmax
Baseline (T0) 68 16 59 16 76 14
Clopidogrel steady state (T1) 45 15* 38 14* 69 15
Ticlopidine steady state (T2) 45 13* 38 13* 44 18*
p  0.05 versus T0; †p  0.05 versus T1.
linical Outcome in Patients Stratified According to Responsivenes
Table 4 Clinical Outcome in Patients Stratified According to R
Responders to Both
Thienopyridines
(n  90)
Clopidogrel Nonr
Ticlopidine Res
(n  25
Death, n (%) 1 (1.1)* 0 (0)
Reinfarction, n (%) 0 (0) 1 (4)*‡
TVR, n (%) 1 (1.1)* 2 (8)*†
MACE, n (%) 2 (2.2) 3 (12)STEMI group; †SA group; ‡attributable to progressional disease in the treated vessel requiring TVR; §re
MACE  major adverse cardiac event; TVR  target vessel revascularization; other abbreviations as inlood to an inactive derivate, and only15% is metabolized
y the cytochrome P450 (CYP) system to generate an active
etabolite. On the other hand, ticlopidine is known to have
higher oral bioavailability (up to 80%) and, unlike clopi-
ogrel, ticlopidine has nonlinear pharmacokinetics, with its
learance decreasing with repeated dosing. Differences in
iver metabolism may be also considered: active metabolites
iffer after clopidogrel or ticlopidine ingestion, and several
soforms of CYP are involved in the metabolism of ticlopi-
ine and clopidogrel. Production of the active metabolite of
lopidogrel strongly depends on isoforms 3A4 and 2C19
18,19); conversely, metabolic pathways of ticlopidine are
ot necessarily dependent on these isoforms.
In keeping with previous evidence, diabetes mellitus
14,15) and smoking (8) were found to have a significant,
lthough weak, influence on thienopyridine responsiveness.
moking seemed to enhance the drug antiplatelet effect.
ctivation of CYP isoenzymes 3A4 and 1A2 by polycyclic
romatic hydrocarbons could explain our finding.
A third-generation thienopyridine, prasugrel, is currently
eing tested in randomized controlled trials. Like ticlopi-
ine and clopidogrel, prasugrel is a prodrug and needs liver
etabolism. Compared with previous thienopyridine gen-
rations, prasugrel is more efficiently transformed into its
ctive metabolite, and it is10 times more potent (12). Our
ata would encourage assessing response to clopidogrel to
dentify those patients with low platelet inhibition at steady
tate who may benefit from alternative compounds such as
iclopidine or prasugrel (20).
tudy limitations. All patients first received clopidogrel
nd then ticlopidine. Although the number of clopidogrel or
iclopidine nonresponders did not differ between STEMI
nd SA patients, an inflammatory environment in STEMI
atients may have influenced platelet reactivity, thus poten-
eness to Clopidogrel and Ticlopidine
to Responsiveness to Clopidogrel and Ticlopidine
nresponders
esponders
25)
Clopidogrel Responders
Ticlopidine Nonresponders
(n  23)
Nonresponders to
Both Thienopyridines
(n  5)
Agglate Aggmax Agglate Aggmax Agglate
68 13 76 16 68 16 80 6 73 5
63 14 46 15* 38 14* 76 5 69 5
35 18*† 70 15† 62 13† 75 5 68 5
Clopidogrel and Ticlopidine
siveness to Clopidogrel and Ticlopidine
ders
rs
Clopidogrel Responders
Ticlopidine Nonresponders
(n  23)
Nonresponders to Both
Thienopyridines
(n  5)
1 (4.3)† 1 (20)*
1 (4.3)*§ 1 (20)†
3 (13)*† 0
5 (22) 2 (40)onsiv
ding
rel No
idine R
(n 
†s to
espon
espon
ponde
)infarction because of stent thrombosis, which required urgent TVR, during ticlopidine intake.
Table 1.
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lthough response to clopidogrel is known to be durable
ver time (15,21), and nonresponse early after steady state is
aintained in the majority of cases even after longer
uration of treatment, it remains theoretically possible that
rossover to ticlopidine has unmasked the effect of time in
ome individuals who were clopidogrel resistant at T1 and
ully responsive to ticlopidine at T2. A randomized cross-
ver investigation would be desirable to confirm the mag-
itude of our findings.
onclusions
ur data, providing critical evidence in favor of drug-
pecific mechanisms after first- and second-generation
hienopyridine resistance, make routine testing for clopi-
ogrel responsiveness an attractive strategy for future clin-
cal trials.
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